OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 4, pp. 652-661
Open Access | Times Cited: 11
Showing 11 citing articles:
Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis
Min Zhuo, Jiahua Li, Leo F. Buckley, et al.
Kidney360 (2022) Vol. 3, Iss. 3, pp. 455-464
Open Access | Times Cited: 33
Min Zhuo, Jiahua Li, Leo F. Buckley, et al.
Kidney360 (2022) Vol. 3, Iss. 3, pp. 455-464
Open Access | Times Cited: 33
Insight into continuous glucose monitoring: from medical basics to commercialized devices
Ayman Chmayssem, Małgorzata Nadolska, Emily Tubbs, et al.
Microchimica Acta (2023) Vol. 190, Iss. 5
Open Access | Times Cited: 20
Ayman Chmayssem, Małgorzata Nadolska, Emily Tubbs, et al.
Microchimica Acta (2023) Vol. 190, Iss. 5
Open Access | Times Cited: 20
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review
Entris Sutrisno, Jajang Japar Sodik, Taufik Muhammad Fakih
Pharmacia (2025) Vol. 72, pp. 1-22
Open Access
Entris Sutrisno, Jajang Japar Sodik, Taufik Muhammad Fakih
Pharmacia (2025) Vol. 72, pp. 1-22
Open Access
Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
Mari Pesonen, Virpi Jylhä, Eila Kankaanpää
JBI Evidence Synthesis (2024) Vol. 22, Iss. 11, pp. 2194-2266
Open Access | Times Cited: 2
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model‐based simulation analysis using 10‐year real‐world data and targeted literature review
Zi‐Yang Peng, Chun‐Ting Yang, Huang‐Tz Ou, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1328-1337
Open Access | Times Cited: 5
Zi‐Yang Peng, Chun‐Ting Yang, Huang‐Tz Ou, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1328-1337
Open Access | Times Cited: 5
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes
Marc Evans, Sasha Berry, Avideh Nazeri, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 639-648
Closed Access | Times Cited: 5
Marc Evans, Sasha Berry, Avideh Nazeri, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 639-648
Closed Access | Times Cited: 5
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Kristoffer Nilsson, Emelie Andersson, Sofie Persson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 748-757
Open Access | Times Cited: 3
Kristoffer Nilsson, Emelie Andersson, Sofie Persson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 748-757
Open Access | Times Cited: 3
Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
Roy Rasalam, Sarah Abdo, Gary Deed, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 901-915
Open Access | Times Cited: 3
Roy Rasalam, Sarah Abdo, Gary Deed, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 901-915
Open Access | Times Cited: 3
